US FDA updates labelling on LABA asthma drugs
This article was originally published in Scrip
Executive Summary
Manufacturers of long-acting beta agonists (LABA) have now updated the labelling of these drugs, following a request to do so made by the US FDA in February (scripnews.com, 19 February 2010). The new labelling emphasises that the LABAs can increase the risk of severe exacerbation of asthma symptoms, leading to hospitalisations, in paediatric and adult patients when used to treat asthma.